Phase I Trial of 17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (17-DMAG), a Heat Shock Protein Inhibitor, Administered Twice Weekly in Patients with Advanced Malignancies

PURPOSE: Phase I dose-escalation study to determine the toxicity and maximum tolerated dose (MTD) of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein 90 (Hsp90) inhibitor, administered on a twice weekly schedule in patients with advanced cancer. EXPERIMENTAL DESIGN...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Kummar, Shivaani, Gutierrez, Martin E., Gardner, Erin R., Chen, Xiaohong, Figg, William D., Zajac-Kaye, Maria, Chen, Min, Steinberg, Seth M., Muir, Christine A., Yancey, Mary Ann, Horneffer, Yvonne R., Juwara, Lamin, Melillo, Giovanni, Ivy, S. Percy, Merino, Maria, Neckers, Len, Steeg, Patricia S., Conley, Barbara A., Giaccone, Giuseppe, Doroshow, James H., Murgo, Anthony J.
Format: Artigo
Jezik:Inglês
Izdano: 2009
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2818572/
https://ncbi.nlm.nih.gov/pubmed/19945858
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2009.10.026
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki